Berkowitz Noah 4

What Happened
Noah Berkowitz, Chief Medical Officer of Arvinas, was awarded equity on February 26, 2026: 45,000 restricted stock units (RSUs) and a 67,000-share derivative award (an option grant). Both grants were reported at $0.00 because they are awards (not open-market purchases or sales) and will vest over multiple years. These are compensation awards, not immediate purchases or sales.

Key Details

• Transaction date: February 26, 2026; Form 4 filed March 2, 2026 (appears to be filed after the typical two-business-day Form 4 deadline).
• Award amounts: 45,000 RSUs (reported A, $0.00) and a 67,000-share option/derivative award (reported A, $0.00).
• Vesting — RSUs (F1): Vest one-quarter each year on Feb 26 of 2027, 2028, 2029 and 2030, contingent on continued service; upon vesting each RSU converts into one share for no consideration.
• Vesting — Option/derivative (F2): One-quarter of the shares underlying the option vest on Feb 26, 2027; remaining shares vest in equal monthly installments through Feb 26, 2030, contingent on continued service.
• Shares owned after the transaction: not specified in the data you provided.
• Transaction code: A = Award/Grant. These grants were not sales and were not exercised or sold at grant.

Context
Equity awards to executives are common as compensation and retention tools; they do not represent an open-market purchase or sale. The option award is a derivative grant (future right to acquire shares subject to vesting and any exercise terms). The apparent late filing may be worth noting for compliance tracking but does not change the nature of the awards.